Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Dynavax Technologies Corporation (DVAX)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
12.72+0.18 (+1.44%)
At close: 04:00PM EST
12.90 +0.18 (+1.42%)
After hours: 07:59PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close12.54
Open12.37
Bid12.40 x 800
Ask12.73 x 2200
Day's Range12.29 - 12.80
52 Week Range7.26 - 17.48
Volume1,188,532
Avg. Volume1,799,241
Market Cap1.526B
Beta (5Y Monthly)1.32
PE Ratio (TTM)N/A
EPS (TTM)-0.78
Earnings DateFeb 27, 2023 - Mar 03, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est24.80
  • Zacks

    Implied Volatility Surging for Dynavax Technologies (DVAX) Stock Options

    Investors need to pay close attention to Dynavax Technologies (DVAX) stock based on the movements in the options market lately.

  • Benzinga

    Dynavax Adjuvant Based COVID-19 Vaccine Lowers The Risk Of Transmission

    Clover Biopharmaceuticals Ltd announced that Clinical Infectious Diseases has published additional data from the SPECTRA Phase 2/3 trial that showed the SCB-2019 COVID-19 vaccine reduced the risk of transmission to household members compared to placebo participants. Clover developed the SCB-2019 antigen, a stabilized trimeric form of the S-protein based on the original strain of the SARS-CoV-2 virus, and combined it with Dynavax Technologies Corp's (NASDAQ: DVAX) CpG 1018 advanced adjuvant and a

  • GlobeNewswire

    Clover’s Vaccine Candidate Reduced Household Transmission of SARS-CoV-2 in Study Published in Clinical Infectious Diseases

    -- The study, a collaboration between Clover and the International Vaccine Institute, showed that a household contact was 84% less likely to get a SARS-CoV-2 infection when the infected household member had received SCB-2019 (CpG 1018/Alum) compared to placebo -- -- Results indicate that vaccination with SCB-2019 can potentially help control the spread of SARS-CoV-2 within communities through the reduction of transmission to household contacts and through previously demonstrated efficacy against

Advertisement
Advertisement